UK regulatory landscape
Semaglutide (Wegovy) in the UK: dispensing landscape
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-24
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Semaglutide (Wegovy) in the UK
Semaglutide, marketed in the UK as Wegovy, is a prescription-only medicine regulated by the MHRA. This page is a regulatory and dispensing-landscape reference, not a recommendation. The UK landscape shifted materially in July 2024 when the cardiovascular outcome indication was approved, broadening the eligible population in NHS England commissioning. It sets out the MHRA authorisation, the NHS pathway and the legitimate private routes. Your UK-licensed prescriber decides whether semaglutide is appropriate, based on the SmPC, PIL and your individual clinical picture.
NHS pathway
NHS England access
The July 2024 cardiovascular outcome indication added a separate NHS access route for adults with established cardiovascular disease, distinct from the tirzepatide NICE TA1026 cohort pathway. NHS access is via specialist weight management services in line with local ICB commissioning.
Read the NHS access editorial →
Private route
CQC-registered clinics
Independent CQC-registered providers in the UK whose formulary includes semaglutide include Numan, Voy, Manual, and Juniper. These app-based programmes pair a prescriber consultation with ongoing clinical review. Whether semaglutide is appropriate is a decision for your prescriber.
UK regulated clinic directory →
Pharmacy route
GPhC-registered pharmacies
UK GPhC-registered pharmacies that dispense semaglutide following a prescriber consultation include Phlo, Pharmacy2U, SimplyMeds, Boots Online Doctor, and Asda Online Doctor. Dispensing requires a valid UK prescription issued by a registered prescriber.
UK regulated pharmacy directory →
Semaglutide and tirzepatide in the UK regulatory context
Semaglutide is a single-mechanism GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Both hold MHRA marketing authorisations for weight management in defined populations as set out in their respective SmPCs. As of July 2024, semaglutide additionally holds a cardiovascular outcome indication in the UK; tirzepatide does not at the time of writing. Editorial commentary on the clinical comparison is published separately. This page does not recommend one molecule over the other for any individual.
Further editorial: tirzepatide vs semaglutide editorial.
Important: POM, your UK-licensed prescriber decides
Semaglutide (Wegovy) is a prescription-only medicine. PeptideClear is an editorial publication, not a pharmacy, not a clinic, and not a prescriber. We do not sell, dispense, or recommend semaglutide for any individual. We publish this page as a UK regulatory and dispensing-landscape reference. Your UK-licensed prescriber, working from the MHRA-approved SmPC, the PIL, NHS England guidance, and your clinical picture, decides whether semaglutide is appropriate for you.
Frequently asked questions
Can I buy Wegovy without a prescription in the UK?
No. Semaglutide (Wegovy) is a prescription-only medicine regulated by the MHRA. It can only be supplied against a valid UK prescription issued by a registered prescriber. Whether it is appropriate for you is a decision for your prescriber, based on the SmPC, the PIL, and your clinical picture.
What changed for Wegovy in the UK in 2026?
In July 2024 a cardiovascular outcome indication was approved, adding a separate NHS access route for adults with established cardiovascular disease. This is distinct from the tirzepatide NICE TA1026 cohort pathway and broadened the eligible population in NHS England commissioning.
What are the legitimate UK routes to semaglutide?
Three routes exist: the NHS pathway via specialist weight management services under ICB commissioning, CQC-registered private clinics, and GPhC-registered pharmacies dispensing after a prescriber consultation. All require a valid UK prescription.
How does semaglutide differ from tirzepatide?
Semaglutide is a single-mechanism GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist. Both hold MHRA authorisations for weight management in defined populations per their SmPCs. As of July 2024 semaglutide additionally holds a UK cardiovascular outcome indication. This page does not recommend one over the other for any individual.